Compare Stocks: NGEN, MNPR, STTK, and CTMX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTMX CytomX Therapeutics	$3.36 +4.7%	$3.46	$1.90 ▼ $8.21	$699.46M	2.12	2.55 million shs	2.38 million shs
MNPR Monopar Therapeutics	$111.93 +0.0%	$107.30	$32.77 ▼ $124.82	$751.03M	1.47	226,479 shs	141,846 shs
NGEN NervGen Pharma	$2.21 -3.1%	$1.84	$1.58 ▼ $6.30	$183.84M	N/A	519,371 shs	798,260 shs
STTK Shattuck Labs	$7.01 -0.4%	$7.08	$0.97 ▼ $8.33	$706.56M	1.08	895,323 shs	751,225 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTMX CytomX Therapeutics	+4.67%	+2.13%	+8.39%	+6.33%	+64.71%
MNPR Monopar Therapeutics	+0.04%	+0.51%	+3.30%	+82.71%	+227.76%
NGEN NervGen Pharma	-3.07%	+10.50%	+36.42%	+10.50%	+220,999,900.00%
STTK Shattuck Labs	-0.43%	-11.27%	-0.85%	+43.94%	+614.72%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTMX CytomX Therapeutics	$3.36 +4.7%	$3.46	$1.90 ▼ $8.21	$699.46M	2.12	2.55 million shs	2.38 million shs
MNPR Monopar Therapeutics	$111.93 +0.0%	$107.30	$32.77 ▼ $124.82	$751.03M	1.47	226,479 shs	141,846 shs
NGEN NervGen Pharma	$2.21 -3.1%	$1.84	$1.58 ▼ $6.30	$183.84M	N/A	519,371 shs	798,260 shs
STTK Shattuck Labs	$7.01 -0.4%	$7.08	$0.97 ▼ $8.33	$706.56M	1.08	895,323 shs	751,225 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTMX CytomX Therapeutics	+4.67%	+2.13%	+8.39%	+6.33%	+64.71%
MNPR Monopar Therapeutics	+0.04%	+0.51%	+3.30%	+82.71%	+227.76%
NGEN NervGen Pharma	-3.07%	+10.50%	+36.42%	+10.50%	+220,999,900.00%
STTK Shattuck Labs	-0.43%	-11.27%	-0.85%	+43.94%	+614.72%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTMX CytomX Therapeutics	2.83	Moderate Buy	$11.90	254.17% Upside
MNPR Monopar Therapeutics	2.86	Moderate Buy	$118.67	6.02% Upside
NGEN NervGen Pharma	2.83	Moderate Buy	$14.00	533.48% Upside
STTK Shattuck Labs	3.00	Buy	$12.78	82.28% Upside

Current Analyst Ratings Breakdown

Latest NGEN, MNPR, STTK, and CTMX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/24/2026	STTK Shattuck Labs	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Strong-Buy	$18.00
8/24/2026	STTK Shattuck Labs	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Strong-Buy	$18.00
8/24/2026	STTK Shattuck Labs	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/19/2026	CTMX CytomX Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/17/2026	MNPR Monopar Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$130.00
8/13/2026	MNPR Monopar Therapeutics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$125.00 ➝ $128.00
8/13/2026	MNPR Monopar Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Overweight ➝ Neutral	$109.00 ➝ $119.00
8/13/2026	CTMX CytomX Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$12.00 ➝ $11.00
8/13/2026	MNPR Monopar Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/12/2026	MNPR Monopar Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$117.00 ➝ $133.00
8/11/2026	STTK Shattuck Labs	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$18.00 ➝ $14.00

(Data available from 9/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTMX CytomX Therapeutics	$76.20M	9.61	N/A	N/A	$0.58 per share	5.79
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	$20.62 per share	N/A
NGEN NervGen Pharma	N/A	N/A	N/A	N/A	$0.03 per share	N/A
STTK Shattuck Labs	$1M	703.52	N/A	N/A	$1.30 per share	5.39

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTMX CytomX Therapeutics	-$17.37M	-$0.50	N/A	N/A	N/A	-435.21%	-38.46%	-30.33%	11/5/2026 (Estimated)
MNPR Monopar Therapeutics	-$13.72M	-$2.17	N/A	N/A	N/A	N/A	-13.08%	-12.79%	11/12/2026 (Estimated)
NGEN NervGen Pharma	-$31.58M	-$0.46	N/A	N/A	N/A	N/A	-1,259.82%	-199.79%	N/A
STTK Shattuck Labs	-$48.81M	-$0.51	N/A	N/A	N/A	N/A	-43.57%	-40.90%	11/10/2026 (Estimated)

Latest NGEN, MNPR, STTK, and CTMX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	NGEN NervGen Pharma	-$0.09	-$0.37	-$0.28	-$0.37	N/A	N/A
8/12/2026	Q2 2026	MNPR Monopar Therapeutics	-$0.6425	-$0.62	+$0.0225	-$0.7920	N/A	N/A
8/11/2026	Q2 2026	STTK Shattuck Labs	-$0.1241	-$0.12	+$0.0041	-$0.12	N/A	N/A
8/6/2026	Q2 2026	CTMX CytomX Therapeutics	-$0.0771	-$0.09	-$0.0129	-$0.09	$12.39 million	$1.42 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTMX CytomX Therapeutics	N/A	N/A	N/A	N/A	N/A
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	N/A
NGEN NervGen Pharma	N/A	N/A	N/A	N/A	N/A
STTK Shattuck Labs	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTMX CytomX Therapeutics	N/A	9.36	9.36
MNPR Monopar Therapeutics	N/A	33.56	33.56
NGEN NervGen Pharma	N/A	1.23	1.23
STTK Shattuck Labs	N/A	27.59	27.59

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTMX CytomX Therapeutics	67.77%
MNPR Monopar Therapeutics	1.83%
NGEN NervGen Pharma	N/A
STTK Shattuck Labs	58.74%

Insider Ownership

Company	Insider Ownership
CTMX CytomX Therapeutics	3.80%
MNPR Monopar Therapeutics	9.70%
NGEN NervGen Pharma	N/A
STTK Shattuck Labs	8.79%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTMX CytomX Therapeutics	170	217.90 million	209.62 million	Optionable
MNPR Monopar Therapeutics	10	6.71 million	6.06 million	Not Optionable
NGEN NervGen Pharma	N/A	80.63 million	N/A	N/A
STTK Shattuck Labs	100	100.36 million	91.54 million	Optionable

NGEN, MNPR, STTK, and CTMX Headlines

Recent News About These Companies

Shattuck Labs: A Receptor-Side Bet On The TL1A Boom

1 hour ago | seekingalpha.com

Shattuck Labs, Inc. (NASDAQ:STTK) Receives Consensus Recommendation of "Buy" from Brokerages

August 31 at 8:13 AM | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Invests $1.99 Million in Shattuck Labs, Inc. $STTK

August 30 at 3:37 AM | marketbeat.com

356,528 Shares in Shattuck Labs, Inc. $STTK Bought by Deutsche Bank AG

August 28, 2026 | marketbeat.com

Shattuck Labs (NASDAQ:STTK) Upgraded at TD Cowen

August 27, 2026 | americanbankingnews.com

Raymond James Financial Upgrades Shattuck Labs (NASDAQ:STTK) to "Strong-Buy"

August 26, 2026 | marketbeat.com

Shattuck Labs (NASDAQ:STTK) Stock Rating Upgraded by TD Cowen

August 25, 2026 | marketbeat.com

Shattuck Labs (NASDAQ:STTK) Stock Price Up 5.5% - Here's What Happened

August 24, 2026 | marketbeat.com

S&G Foundation Makes New $3.02 Million Investment in Shattuck Labs, Inc. $STTK

August 23, 2026 | marketbeat.com

Shattuck Labs, Inc. (STTK) is a Great Momentum Stock: Should You Buy?

August 20, 2026 | zacks.com

Shattuck Labs (NASDAQ:STTK) Cut to Hold at Wall Street Zen

August 15, 2026 | marketbeat.com

Wall Street Analysts Believe Shattuck Labs (STTK) Could Rally 85.31%: Here's is How to Trade

August 13, 2026 | zacks.com

Q3 EPS Estimates for Shattuck Labs Raised by HC Wainwright

August 13, 2026 | marketbeat.com

Shattuck Labs Advances SL-325 Crohn’s Trial Toward a Key Value Milestone

August 12, 2026 | tipranks.com

Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights

August 11, 2026 | markets.businessinsider.com

Shattuck Labs Releases Q2 2026 10-Q Filing Highlighting Key Risk Factors and Share Count

August 11, 2026 | kalkinemedia.comK

HC Wainwright Cuts Shattuck Labs (NASDAQ:STTK) Price Target to $14.00

August 11, 2026 | marketbeat.com

Shattuck Labs (NASDAQ:STTK) Releases Earnings Results, Hits Expectations

August 11, 2026 | marketbeat.com

Shattuck Labs Reports Positive Phase 1 Data for SL-325 and Advances DR3 Pipeline with Phase 2b Crohn’s Study Planned for 2026

August 11, 2026 | quiverquant.comQ

Shattuck Labs, Inc. $STTK Stock Holdings Lifted by Renaissance Technologies LLC

August 8, 2026 | marketbeat.com

Shattuck Labs, Inc. (NASDAQ:STTK) Given Average Rating of "Moderate Buy" by Brokerages

August 6, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NGEN, MNPR, STTK, and CTMX Company Descriptions

CytomX Therapeutics NASDAQ:CTMX

$3.36 +0.15 (+4.67%)

Closing price 08/31/2026 04:00 PM Eastern

Extended Trading

$3.40 +0.04 (+1.34%)

As of 08:44 AM Eastern

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Monopar Therapeutics NASDAQ:MNPR

$111.93 +0.04 (+0.04%)

Closing price 08/31/2026 04:00 PM Eastern

Extended Trading

$111.76 -0.17 (-0.15%)

As of 08:33 AM Eastern

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

NervGen Pharma NASDAQ:NGEN

$2.21 -0.07 (-3.07%)

As of 08/31/2026 04:00 PM Eastern

NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada.

Shattuck Labs NASDAQ:STTK

$7.01 -0.03 (-0.43%)

Closing price 08/31/2026 04:00 PM Eastern

Extended Trading

$7.18 +0.18 (+2.50%)

As of 08:54 AM Eastern

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NGEN, MNPR, STTK, and CTMX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NGEN, MNPR, STTK, and CTMX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NGEN, MNPR, STTK, and CTMX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NGEN, MNPR, STTK, and CTMX Company Descriptions

CytomX Therapeutics NASDAQ:CTMX

Monopar Therapeutics NASDAQ:MNPR

NervGen Pharma NASDAQ:NGEN

Shattuck Labs NASDAQ:STTK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NGEN, MNPR, STTK, and CTMX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NGEN, MNPR, STTK, and CTMX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NGEN, MNPR, STTK, and CTMX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NGEN, MNPR, STTK, and CTMX Company Descriptions

CytomX Therapeutics NASDAQ:CTMX

Monopar Therapeutics NASDAQ:MNPR

NervGen Pharma NASDAQ:NGEN

Shattuck Labs NASDAQ:STTK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools